Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure
Milton Packer(Dana-Farber/Harvard Cancer Center), Johannes Holzmeister(British Heart Foundation), Mark C. Petrie(British Heart Foundation), Richard Holcomb(IQVIA (United States)), Frank Ruschitzka(Kantonsspital St. Gallen), Piotr Ponikowski(Wroclaw Medical University), Janet Wittes(Deloitte (United States)), Gerasimos Filippatos(National and Kapodistrian University of Athens), John J.V. McMurray(University of Glasgow), W. Frank Peacock(Hennepin Healthcare Research Institute), William T. Abraham(The Ohio State University), Dirk J. van Veldhuisen(University Medical Center Groningen), Alexandre Mebazaa(Marqueurs cardiovasculaires en situation de stress), Lisa Kowarski(British Heart Foundation), Aldo P. Maggioni(Health Care Foundation), Henry Krum(Australian Regenerative Medicine Institute), Kenneth Dickstein, Stefan D. Anker(Bayer (Germany)), Christopher M. O’Connor(Inova Health System), Mark Schactman(British Heart Foundation)
Cited by 313
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
|European Journal of Heart Failure|2016|5.9k